

## HR 3932

Strengthening of FDA Integrity Act of 2009

**Congress:** 111 (2009–2011, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Oct 27, 2009

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 28, 2009)

**Official Text:** <https://www.congress.gov/bill/111th-congress/house-bill/3932>

### Sponsor

**Name:** Rep. Barton, Joe [R-TX-6]

**Party:** Republican • **State:** TX • **Chamber:** House

### Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Blackburn, Marsha [R-TN-7]	R · TN		Oct 27, 2009
Rep. Bono Mack, Mary [R-CA-45]	R · CA		Oct 27, 2009
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Oct 27, 2009
Rep. Shimkus, John [R-IL-19]	R · IL		Oct 27, 2009
Rep. Sullivan, John [R-OK-1]	R · OK		Oct 27, 2009
Rep. Terry, Lee [R-NE-2]	R · NE		Oct 27, 2009
Rep. Walden, Greg [R-OR-2]	R · OR		Oct 27, 2009

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 28, 2009

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

## Summary (as of Oct 27, 2009)

---

Strengthening of FDA Integrity Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act to apply debarment provisions currently applicable to abbreviated new drugs to any drug products, including new drugs, animal drugs, exported drugs, biological products, and medical devices.

Expands the conditions under which persons (i.e., partnerships, corporations, and associations) are subject to mandatory and permissive debarment preventing such persons from submitting an application for approval of a drug product.

Requires the Secretary of Health and Human Services (HHS), in determining the appropriateness and the period of debarment, to consider whether debarment will affect the public health because sufficient quantities of the drug would not be available.

Requires the Secretary to annually report to Congress on the implementation of debarment provisions.

## Actions Timeline

---

- **Oct 28, 2009:** Referred to the Subcommittee on Health.
- **Oct 27, 2009:** Introduced in House
- **Oct 27, 2009:** Referred to the House Committee on Energy and Commerce.